Ligand partner GSK gains priority review designation for Promacta/Revolade
SAA is a rare disorder in which the bone marrow fails to make enough new blood cells. There are no approved therapies available for SAA patients who are
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
Anoro Ellipta is a combination anticholinergic/long-acting beta2-adrenergic agonist (anticholinergic/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.